Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin lymphoma (HL)

被引：0
|
作者：
Younes, A. [5 ]
Kuruvilla, J. [4 ]
Pro, B. [5 ]
Wedgwood, A. [5 ]
Li, Z. [3 ]
Drouin, M. [3 ]
Patterson, T. [3 ]
Ward, R. [2 ]
Martell, R. E. [3 ]
Bociek, R. G. [1 ]
机构：
[1] Univ Nebraska Med Ctr, Dept Internal Med, Omaha, NE USA
[2] Pharm Corp, Clin Operat, Boulder, CO USA
[3] Drug Dev MethylGene Inc, Montreal, PQ, Canada
[4] Princess Margaret Hosp, Dept Med Oncol & Hematol, Toronto, ON M4X 1K9, Canada
[5] Univ Texas Houston, MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：128 / 128
页数：1
相关论文
共 50 条
  • [1] Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin Lymphoma (HL)
    Bociek, R. G.
    Kuruvilla, J.
    Pro, B.
    Wedgwood, A.
    Li, Z.
    Drouin, M.
    Patterson, T.
    Ward, R.
    Martell, R. E.
    Younes, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [2] A phase II study of MGCD0103, a novel oral isotype-selective histone deacetylase inhibitor, in patients with relapsed or refractory Hodgkin lymphoma
    Younes, A.
    Pro, B.
    Fanale, M.
    McLaughlin, P.
    Neelapu, S.
    Fayad, L.
    Wedgwood, A.
    Li, Z.
    Ward, R.
    Martell, R. E.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 28 - 29
  • [3] Mocetinostat (MGCD0103), An Isotype-Selective Histone Deacetylase (HDAC) Inhibitor, Produces Clinical Responses In Relapsed/Refractory Hodgkin Lymphoma (HL): Update From a Phase II Clinical Study
    Younes, Anas
    Bociek, R. Gregory
    Kuruvilla, John
    Laneuville, Pierre
    Fung, Henry C.
    Drouin, Michel
    Patterson, Tracy
    Besterman, Jeffrey
    Martell, Robert E.
    BLOOD, 2010, 116 (21) : 735 - 735
  • [4] Isotype-selective HDAC inhibitor MGCD0103 decreases serum TARC concentrations and produces clinical responses in heavily pretreated patients with relapsed classical Hodgkin lymphoma (HL)
    Younes, Anas
    Pro, Barbara
    Fanale, Michelle
    McLaughlin, Peter
    Neelapu, Sattva
    Fayad, Luis
    Wedgwood, Amanda
    Buglio, Daniela
    Patterson, Tracy
    Dubay, Marja
    Li, Zuomei
    Martell, Robert E.
    Ward, M. Renee
    Bociek, R. Gregory
    BLOOD, 2007, 110 (11) : 756A - 756A
  • [5] Promising antitumor activity with MGCD0103, a novel isotype-selective histone deacetylase inhibitor
    Le Tourneau, Christophe
    Siu, Lillian L.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2008, 17 (08) : 1247 - 1254
  • [6] Treatment of relapsed or refractory lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: Interim results from a phase II study
    Younes, Anas
    Wedgwood, Amanda
    McLaughlin, Peter
    Andreadis, Charalambos
    Assouline, Sarit E.
    Li, Zuomei
    Martell, Robert E.
    Dubay, Marja
    Patterson, Tracy-Ann
    Ward, Michelle R.
    Crump, Michael
    BLOOD, 2007, 110 (11) : 758A - 758A
  • [7] Treatment of relapsed or refractory non-hodgkin lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: Interim results from a phase II study
    Younes, A.
    Andreadis, C.
    Assouline, S.
    Rizzieri, D.
    Wedwood, A.
    McLaughlin, P.
    Laille, E.
    Li, Z.
    Martell, R. E.
    Crump, M.
    ANNALS OF ONCOLOGY, 2008, 19 : 162 - 162
  • [8] Synergistic antitumor activity of the isotype-selective histone deacetylase inhibitor MGCD0103 in combination with gemcitabine.
    Nguyen, H
    Gravel, S
    MacLeod, AR
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9153S - 9154S
  • [9] Treatment of relapsed or refractory non-hodgkin lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: Interim results from a phase II study
    Crump, M.
    Andreadis, C.
    Assouline, S.
    Rizzieri, D.
    Wedgwood, A.
    McLaughlin, P.
    Laille, E.
    Li, Z.
    Martell, R. E.
    Younes, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo
    Fournel, Marielle
    Bonfils, Claire
    Hou, Yu
    Yan, Pu Theresa
    Trachy-Bourget, Marie-Claude
    Kalita, Ann
    Liu, Jianhong
    Lu, Ai-Hua
    Zhou, Nancy Z.
    Robert, Marie-France
    Gillespie, Jeffrey
    Wang, James J.
    Ste-Croix, Helene
    Rahil, Jubrail
    Lefebvre, Sylvain
    Moradei, Oscar
    Delorme, Daniel
    MacLeod, A. Robert
    Besterman, Jeffrey M.
    Li, Zuomei
    MOLECULAR CANCER THERAPEUTICS, 2008, 7 (04) : 759 - 768
12345